INTRODUCTION
Weight gain is commonly seen when patients are started on subcutaneous (SC) insulin. In the United Kingdom Prospective Diabetes Study, those assigned insulin gained 4 kg more that those assigned conventional therapy at 10 years (1) . Given that the majority of patients with type 2 diabetes are overweight or obese (2, 3) , additional weight gain is clearly a concern. Furthermore, while patients with type 1 diabetes were historically often underweight, the greater use of an intensified treatment approach to achieve the benefits of improved glycemic control is associated with greater weight gain than conventional treatment (4) . Fear of weight gain, along with factors such as reluctance to self-inject and fear of hypoglycemia, is a frequent deterrent to initiating insulin therapy and has been linked to reduced treatment adherence in both patients with type 1 diabetes and those with type 2 diabetes (5).
In type 2 diabetes, the beta-cell dysfunction that leads to impaired insulin secretion is progressive, and eventually patients will require a treatment strategy that includes insulin, either alone or with oral agents (6). Data from the five trials were pooled and statistical methods repeated those used in the original trials, namely an ANCOVA model with model terms for baseline values, study, and treatment group.
RESULTS
This analysis included 1048 patients with type 1 diabetes (527 EXU; 521 SC insulin) and 912 patients with type 2 diabetes (460 EXU; 452 SC insulin). Baseline body weight and A1C levels were similar between the EXU and comparator groups (Table 1) .
Less weight gain was observed with EXU regimens compared to SC insulin regimens in adult patients with type 1 or type 2 diabetes. The differences in the treatment effect on body weight were consistent across gender. In patients with type 1 diabetes, a 0.2 kg increase was noted with EXU compared to a 1.1. kg increase with SC insulin. Patients with type 2 diabetes gained only half as much weight on a regimen including EXU compared with regimens that only included SC insulin (0.7 kg vs 1.6 kg, respectively). The adjusted mean change in weight was statistically different in patients treated with a regimen including EXU vs an SC insulin only regimen for both type 1 diabetes −0.87 kg (95% CI −1.24, −0.50) and type 2 diabetes −0.93 kg (95% CI −1.39, −0.48).
Despite differences in weight changes, reductions in A1C were comparable in both treatment groups ( 
CONCLUSIONS
Significantly less weight gain was observed at 6 months with regimens including EXU therapy compared to SC insulin only regimens in adult patients with type 1 or type 2 diabetes. Long-term data have confirmed that these differences in weight gain are sustained at 2 years (Table 1 ) (9,11). Compared to SC insulin, patients with type 1 diabetes receiving EXU only gained a modest amount of weight; patients with type 2 diabetes gained half as much weight.
Comparable mean changes from baseline A1C were observed with EXU and SC insulin only regimens in both the type 1 and type 2 diabetes groups, thus less weight gain with EXU is not explained by differences in glycemic control. The incidence of hypoglycemia with EXU regimens was consistent with that associated with SC insulin use. Both the frequency and nature of hypoglycemia with EXU are comparable to SC insulin, with most events being mild to moderate in severity (12).
The authors acknowledge that this was an analysis of 6-month data only, a relatively short time period given the life-long need for insulin in patients with diabetes. However, in well-controlled animal studies comparing inhaled and matched intravenous insulin administration, inhalation of insulin was associated with markedly increased peripheral and decreased hepatic glucose uptake (13). Pending confirmation in humans this finding may point to significant differences between routes of insulin administration potentially affecting metabolic energy balances. 
